Skip to content
Peptide research

MOTS-c

Also known as Mitochondrial ORF of 12S rRNA type-c
Category
Longevity & Anti-Aging
Administration routes
Injectable
Regulatory status
Not FDA-approved

A mitochondria-derived peptide that activates AMPK signaling, marketed for metabolic health, fat loss, and exercise capacity. Its best-supported effects, better glucose handling and exercise capacity, come mostly from animal and mechanistic data; native MOTS-c has never been tested in a controlled human trial, so the human case is unproven. Most commercial supply is research-grade, with purity reported as low as 60 percent. Not approved in the US.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

MOTS-c is a 16-amino-acid peptide naturally produced by your mitochondria -- the energy factories inside every cell. Discovered in 2015 at the USC Leonard Davis School of Gerontology, it was a landmark finding because it revealed mitochondria encode their own signaling molecules beyond just energy production. MOTS-c is often called an "exercise mimetic" because it reproduces many of the metabolic benefits of physical activity, including improved blood sugar control, enhanced fat burning, and better physical performance. Natural MOTS-c levels decline with age and increase with exercise.

How it works in the body

A mitochondria-derived peptide encoded by mitochondrial DNA. It activates AMPK signaling, which increases cellular glucose uptake and fatty acid oxidation. In skeletal muscle, it improves insulin sensitivity and exercise capacity. It can also translocate to the cell nucleus during stress to regulate gene expression.

Research overview

MOTS-c has generated roughly 200 publications since 2015, though the vast majority are cell culture and animal studies. In mice, MOTS-c prevents diet-induced obesity and insulin resistance (Lee et al., 2015), enhances physical performance across all age groups, and improves healthspan even when started late in life (Reynolds et al., 2021). A genetic variant of MOTS-c found in Northeast Asian populations was linked to exceptional longevity in Japanese centenarians (Fuku et al., 2015). Human data is still limited: observational studies show declining levels with age, and a stabilized MOTS-c analog (CB4211) completed early Phase 1 trials showing safety and modest signals for liver enzymes and glucose in obese patients with fatty liver disease. No Phase 2 or Phase 3 trials of native MOTS-c have been completed, so the promising animal results still need rigorous human confirmation.

Who researches MOTS-c?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People exploring muscle growth and performance

    Researched for potential effects on lean mass, strength, or athletic performance.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data.

  • Those with Hypoglycemia-prone individuals

    Moderate

    MOTS-c enhances glucose uptake. May cause hypoglycemia in combination with insulin or sulfonylureas.

Safety & interactions

Do not use if

  • Hypoglycemia-prone individuals

    Moderate

    MOTS-c enhances glucose uptake. May cause hypoglycemia in combination with insulin or sulfonylureas.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • Native MOTS-c never given to humans in a controlled clinical trial

    High

    CohBar CB4211 Phase 1a/1b (GlobeNewswire 2021-08-10); no ClinicalTrials.gov entry for native MOTS-c

  • Most commercial MOTS-c is research-grade (purity as low as 60%)

    High

    Innerbody MOTS-c review 2026 (source of the ~60% figure; consumer testing, not a controlled study); general research-chemical peptide quality/endotoxin concerns; FDA unapproved-drug enforcement context

  • Enhances glucose uptake; hypoglycemia risk with diabetes meds

    Moderate

    Lee 2015 Cell Metab PMC4350682 (mechanism); directional support from CB4211 analog glucose reduction (GlobeNewswire 2021-08-10)

  • Injection site reactions (CB4211 analog Phase 1)

    Low

    CohBar CB4211 Phase 1a/1b topline (GlobeNewswire 2021-08-10)

  • Anecdotal palpitations and elevated heart rate

    Low

    User anecdote (no controlled data)

  • Nausea, bloating, mild diarrhea (user reports)

    Low

    User anecdote (no controlled data)

Interaction summary(6)

Rated by direction with this peptide

  • Insulin

    CautionModerate

    MOTS-c increases insulin-independent, AMPK/GLUT4-driven muscle glucose uptake, so combining it with injected insulin can additively lower blood glucose and raise hypoglycemia risk; monitor glucose.

    Lee 2015 Cell Metab PMC4350682 (mechanism)

  • Sulfonylureas / insulin secretagogues (e.g., glipizide, glyburide)

    CautionModerate

    These force endogenous insulin release while MOTS-c independently boosts glucose disposal, so using the two together can add up to hypoglycemia; dose reduction and monitoring may be warranted.

    Mechanism-based (Lee 2015 PMC4350682; antidiabetic hypoglycemia pharmacology)

  • Metformin

    SynergisticLow

    Both activate AMPK by complementary routes (metformin curbs hepatic gluconeogenesis, MOTS-c raises muscle glucose uptake), giving additive glucose-lowering that is usually beneficial but should be glucose-monitored when combined.

    Mechanism-based (Lee 2015 PMC4350682; metformin AMPK, PMC4311245)

  • SGLT2 inhibitors and other glucose-lowering agents

    CautionTheoretical

    Layering another glucose-lowering agent on MOTS-c could additively reduce blood glucose; interaction is mechanistic/theoretical with no controlled data in the native peptide.

    Mechanism-based (Lee 2015 PMC4350682)

  • Glucocorticoids (e.g., prednisone)

    ProtectiveTheoretical

    MOTS-c mechanistically opposes glucocorticoid-driven muscle atrophy (myostatin/FOXO1) and steroid-induced insulin resistance, so it may theoretically counter these effects; protective direction is inferred from mechanism, not demonstrated clinically.

    Mechanism-based (Kumagai 2021 PMC8238132; Lee 2015 PMC4350682)

  • Aerobic / endurance exercise

    SynergisticLow

    MOTS-c is an exercise-induced, exercise-mimetic peptide (endogenous muscle levels rise with training); exogenous dosing plausibly complements training-driven AMPK activation and performance adaptations.

    Reynolds 2021 Nat Commun s41467-020-20790-0; Hyatt 2022 PMID 35808870

Known risks(8)

  • No established human safety profile

    High

    Native MOTS-c has never been administered to humans in a controlled clinical trial. All safety data is extrapolated from animal studies or from the CB4211 analog trial. Unknown long-term effects.

  • Research-grade product purity concerns

    High

    Most commercially available MOTS-c is research-grade with purity as low as 60%. Impurities may be toxic and can trigger immunogenic reactions where the body mounts an immune response against the peptide.

  • Hypoglycemia risk

    Moderate

    MOTS-c enhances insulin sensitivity and glucose uptake. Combined with diabetes medications or in fasting states, this could theoretically cause dangerous drops in blood sugar.

  • Injection site reactions

    Low-Moderate

    The CB4211 Phase 1 trial reported injection site reactions as the most common adverse event. Anecdotal reports of subcutaneous MOTS-c include redness, swelling, and irritation at injection sites.

  • Cardiovascular effects (heart palpitations, increased heart rate)

    Moderate

    Anecdotal reports from self-experimenters include heart palpitations and elevated heart rate. No controlled data exists to characterize cardiovascular risk.

  • Gastrointestinal disturbance

    Low-Moderate

    User reports include nausea, bloating, and mild diarrhea, possibly related to metabolic shifts induced by the peptide.

  • Insomnia and fatigue

    Low

    Some users report sleep disturbances and paradoxical fatigue, potentially related to metabolic adaptation and cellular energy shifts.

  • Unknown effects on cancer biology

    MOTS-c affects cell proliferation, AMPK signaling, and metabolic pathways involved in cancer. While some preclinical evidence suggests anti-cancer effects (ovarian cancer suppression via USP7-LARS1), the net effect on human cancer risk is unknown.

Drug interactions(6)

  • Insulin and insulin secretagogues

    Theoretical additive hypoglycemia risk. MOTS-c enhances insulin sensitivity and glucose uptake in skeletal muscle via AMPK activation. Combined use could potentiate blood sugar lowering beyond intended levels.

  • Metformin and other biguanides

    Overlapping mechanism of action — both activate AMPK pathway. Theoretical risk of excessive AMPK activation, enhanced lactate production, or additive metabolic effects. A study in breast cancer patients (Cuyas et al. 2022, PMID 36490309) found metformin did not significantly alter circulating MOTS-c levels, but pharmacodynamic interaction cannot be ruled out.

  • Statins (HMG-CoA reductase inhibitors)

    Theoretical interaction — statins can affect mitochondrial function and both statins and MOTS-c impact cellular energy metabolism. No clinical data available.

  • Folate supplements and antifolates (e.g., methotrexate)

    MOTS-c's primary mechanism involves inhibiting folate metabolism and de novo purine biosynthesis. Antifolate drugs like methotrexate share this pathway, potentially creating additive or antagonistic effects on folate metabolism.

  • Other peptide therapies (GLP-1 agonists, GH secretagogues)

    No documented interactions, but combined use of multiple metabolic peptides could have unpredictable synergistic effects on glucose metabolism, insulin sensitivity, and energy homeostasis.

  • Immunosuppressants

    Theoretical concern — MOTS-c modulates immune responses and inflammatory pathways (NRF2, AMPK). May interfere with immunosuppressive drug efficacy. No clinical data.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
197
Human Studies
5

Over 95% of MOTS-c evidence comes from cell culture and animal (primarily mouse) studies. Human data consists of observational/correlational studies measuring endogenous MOTS-c levels, a few exercise intervention studies measuring MOTS-c as a biomarker (not administering it), and one Phase 1a/1b trial of the analog CB4211 enrolling 88 subjects: 65 healthy participants and 23 participants with obesity and NAFLD, of whom 20 completed the Phase 1b assessments. No human trials have directly tested native MOTS-c injection for any therapeutic purpose. The preclinical evidence is robust and consistent across multiple disease models, but clinical translation remains in very early stages.

Researched for(8)

Rated by confidence in the evidence

  • Improved insulin sensitivity and glucose metabolism

    Medium

    Consistent animal data and an AMPK/GLUT4 mechanism; one small human analog trial showed lower glucose.

    Lee 2015 Cell Metab PMC4350682 (DOI 10.1016/j.cmet.2015.02.009); Kim 2019 Physiol Rep DOI 10.14814/phy2.14171; human analog glucose signal: CohBar CB4211 Phase 1a/1b topline (GlobeNewswire, 2021-08-10)

  • Reduced obesity and fat accumulation

    Low

    Strong animal weight and liver-fat data; the human analog trial showed no drug-versus-placebo benefit.

    Lee 2015 Cell Metab PMC4350682; CohBar CB4211 Phase 1a/1b topline (GlobeNewswire/BioSpace, 2021-08-10) — liver-fat reduction seen in both drug and placebo arms; body weight only a trend

  • Enhanced physical performance and exercise capacity

    Medium

    Extensive animal data shows better running capacity; no human performance trial yet.

    Reynolds 2021 Nat Commun s41467-020-20790-0; Hyatt 2022 Physiol Rep PMID 35808870 / PMC9270643

  • Anti-muscle atrophy and myostatin reduction

    Speculative

    Rests on a 2021 cell and mouse study that also found an inverse association between MOTS-c and myostatin in humans; no human treatment trial.

    Kumagai 2021 AJP-Endo PMC8238132 (DOI 10.1152/ajpendo.00275.2020)

  • Bone metabolism support and anti-osteoporosis effects

    Low

    Animal and cell data show reduced bone loss via AMPK; no human evidence.

    Ming 2016 BBRC PMID 27237975; review Front Physiol 2023 PMC10185875

  • Cardiovascular and cardioprotective effects

    Low

    Multiple animal studies plus a human observational link; no interventional trial in people.

    Diabetic-rat: PMC9846618; H9c2: Springer DOI 10.1007/s13239-021-00589-w; human cross-sectional: Biomedicines 2026 (MDPI 2227-9059/14/4/918)

  • Anti-inflammatory and antioxidant activity

    Low

    Consistent cell and animal data via NF-kB and Nrf2 pathways; no human trials.

    H9c2 Nrf2/NF-kB: DOI 10.1007/s13239-021-00589-w; review PMC9854231

  • Potential longevity association

    Speculative

    A 2015 genetic hypothesis that larger cohorts did not confirm; no lifespan benefit shown.

    Fuku 2015 Aging Cell PMC4693465 (DOI 10.1111/acel.12389); corrective analysis Aging (Albany) PMID 33468709 / PMC7880332 (DOI 10.18632/aging.202529)

Benefits(8)

  • Improved insulin sensitivity and glucose metabolism

    Lee et al. 2015 (Cell Metabolism) — MOTS-c prevented age- and HFD-induced insulin resistance in mice via AMPK activation. Yin et al. 2022 (Pharmacological Research) — MOTS-c alleviated hyperglycemia and insulin resistance in gestational diabetes mouse model.

  • Reduced obesity and fat accumulation

    Lee et al. 2015 (Cell Metabolism) — MOTS-c prevented diet-induced obesity in mice. Lu et al. 2019 (J Mol Med) — MOTS-c prevented ovariectomy-induced obesity via AMPK-mediated adipose homeostasis and brown fat activation.

  • Enhanced physical performance and exercise capacity

    Reynolds et al. 2021 (Nature Communications) — MOTS-c significantly enhanced physical performance in young, middle-aged, and old mice; late-life treatment (23.5 mo) increased physical capacity and healthspan.

  • Anti-muscle atrophy and myostatin reduction

    Kumagai et al. 2021 (Am J Physiol Endocrinol Metab) — MOTS-c decreased myostatin levels in obese mice and prevented palmitic acid-induced atrophy in myotubes via AKT/mTORC2/CK2 pathway.

  • Bone metabolism support and anti-osteoporosis effects

    Yi et al. 2023 (Front Physiol) — Review of MOTS-c promoting osteoblast proliferation, differentiation, and mineralization while inhibiting osteoclast formation. Ming et al. 2016 (BBRC) — MOTS-c suppressed ovariectomy-induced bone loss via AMPK activation in mice.

  • Cardiovascular and cardioprotective effects

    Zhong et al. 2022 (J Cell Mol Med) — MOTS-c prevented heart failure development in pressure-overload mouse model. Wu et al. 2023 (Acta Biochim Biophys Sin) — MOTS-c reduced LPS-induced septic cardiomyopathy inflammation and oxidative stress.

  • Anti-inflammatory and antioxidant activity

    Kim et al. 2018 (Cell Metabolism) — MOTS-c regulates ARE-containing genes via NRF2 interaction. Zhang et al. 2024 (Antioxidants) — MOTS-c alleviated radiation pneumonitis via Nrf2-dependent mechanism.

  • Potential longevity association

    Fuku et al. 2015 (Aging Cell) — m.1382A>C polymorphism in MOTS-c region is specific to Northeast Asian populations and may contribute to exceptional longevity in Japanese centenarians.

Key studies(5)

  1. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

    Original research (preclinical)Mouse study (multiple cohorts)Various (acute and chronic dosing)

    Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P

    Cell Metabolism

    2015

    Discovery paper. Identified MOTS-c as a 16-amino-acid peptide encoded in mitochondrial 12S rRNA. Showed MOTS-c targets skeletal muscle, inhibits folate cycle/purine biosynthesis, activates AMPK, and prevents age- and diet-induced insulin resistance and obesity in mice.

  2. Kim KH, Son JM, Benayoun BA, Lee C

    Cell Metabolism

    2018

    Demonstrated that MOTS-c translocates to the nucleus under metabolic stress in an AMPK-dependent manner, where it regulates genes with antioxidant response elements (ARE) and interacts with NRF2. First evidence of a mitochondrial-encoded factor actively controlling nuclear gene expression.

  3. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

    Original research (preclinical + human observational)Multiple mouse cohorts (young/middle/old); human exercise cohortIntermittent treatment 3x/week in aged mice; acute exercise in humans

    Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Lee C

    Nature Communications

    2021

    MOTS-c enhanced physical performance in mice of all ages. Late-life initiated intermittent MOTS-c treatment increased physical capacity and healthspan in aged (23.5 mo) mice. In humans, exercise induced endogenous MOTS-c expression in skeletal muscle (11.9-fold increase by Western blot) and circulation following a single bout of stationary cycling, with muscle levels remaining elevated at four hours but circulating levels returning to baseline by then.

  4. MOTS-c reduces myostatin and muscle atrophy signaling

    Original research (preclinical + human correlational)Mouse HFD model; C2C12 cell culture; human plasma correlation studyVarious

    Kumagai H, Coelho AR, Wan J, Mehta HH, Yen K, Huang A, Zempo H, Fuku N, Maeda S, Oliveira PJ, Cohen P, Kim SJ

    American Journal of Physiology - Endocrinology and Metabolism

    2021

    Plasma MOTS-c levels inversely correlate with myostatin in humans. MOTS-c decreased myostatin via AKT/FOXO1 pathway, prevented muscle atrophy in obese mice and fat-stressed myotubes. Suggests therapeutic potential for sarcopenia.

  5. Phase 1a/1b Study of CB4211 (MOTS-c Analog) for NASH and Obesity

    Phase 1a/1b clinical trial88 enrolled: 65 healthy adults and 23 participants with obesity and NAFLD; 20 completed Phase 1b assessments1 week (1a) / 4 weeks (1b), 25 mg SC daily

    CohBar Inc.

    ClinicalTrials.gov / AASLD 2021 Poster

    2021

    CB4211 was well-tolerated with no serious adverse events. In NAFLD patients, ALT reduced 25%, AST reduced 17%, glucose reduced 6% vs placebo. Most common AE was injection site reaction. First mitochondrial-derived peptide analog tested in humans.

What research suggests over time

  • Weeks 2-4

    Phase 1b (CB4211 analog)

    No human timeline established for native MOTS-c; the CB4211 analog was well tolerated in a Phase 1b trial in obese NAFLD patients.

  • Months 2-3

    Preclinical (mouse)

    In aged mice, 7 days of treatment restored insulin sensitivity to youthful levels and improved physical capacity.

  • Long-term

    Preclinical + human observational

    Late-life intermittent treatment improved healthspan in 23.5-month-old mice (Reynolds 2021 Nat Commun). Endogenous MOTS-c rises 11.9-fold during human exercise.

Regulation & availability

Why researchers look at it

A mitochondrial-derived signaling peptide discovered after humanin, with a genetic variant linked to exceptional longevity in Japanese centenarians. Mice given MOTS-c resist obesity, improve insulin sensitivity, and gain exercise capacity even when treatment starts late in life. A stabilized analog (CB4211) cleared Phase 1 showing safety and modest metabolic signals in obese patients with fatty liver disease.

Estimated cost
No approved product and no verified reference price
FDA status
Not FDA-approved for any indication. No publicly confirmed IND for native MOTS-c was identified; the analog CB4211 underwent a separate IND-authorized trial. FDA lists MOTS-c among substances whose nominations were withdrawn and retains safety concerns. It is not on FDA's 503A bulks list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound MOTS-c acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's Pharmacy Compounding Advisory Committee reviewed it in July 2026; FDA's drug reviewers recommended against listing it and the committee voted in favor, as HHS's October 2026 policy records; FDA has not posted minutes or changed the list.
WADA status
Banned at all times. MOTS-c is explicitly listed under S4.4.1, AMPK activators, on the 2026 WADA Prohibited List. It was added as a named AMPK-activator example in 2025; it was not a named S0 example in 2024. A TUE is highly unlikely, and any application is assessed under the standard medical criteria.
Prescribability
Not prescribable as an FDA-approved medication. MOTS-c has no FDA approval for any indication. It is not on FDA's list of bulk substances pharmacies may use for compounding; FDA lists it among substances whose nominations were withdrawn. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound MOTS-c acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. Pharmaceutical-grade MOTS-c is scarce; most commercially available product is research-grade with variable purity (sometimes as low as 60%).
Availability
MOTS-c is NOT available as an approved pharmaceutical product. Unregulated products sold online vary widely in purity and lack pharmaceutical-grade quality controls. Some telehealth and anti-aging clinics offer MOTS-c through questionable supply chains, often without proper regulatory compliance. FDA lists MOTS-c among substances whose compounding nominations were withdrawn and retains safety concerns. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound MOTS-c acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. Unregulated products sold online and outsourcing facilities are outside it.

International status

  • EU

    Not approved

  • US

    MOTS-c is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound MOTS-c acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing MOTS-c; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.

  • Australia

    Not approved

Regulatory timeline(11)

  1. 2015-03
    MOTS-c discovered and published by Lee, Cohen et al. at USC in Cell Metabolism (PMID 25738459). First identification of a functional signaling peptide in mitochondrial 12S rRNA.
  2. 2015-09
    Fuku et al. publish population genetics study linking MOTS-c variant to exceptional longevity in Japanese centenarians (Aging Cell, PMID 26289118).
  3. 2018-07
    Kim et al. publish nuclear translocation mechanism in Cell Metabolism (PMID 29983246), establishing MOTS-c as first mitochondrial-encoded nuclear gene regulator.
  4. 2018-07
    CohBar Inc. begins Phase 1a clinical trial of CB4211 (stabilized MOTS-c analog) for NASH and obesity (NCT03998514).
  5. 2020-01
    CohBar completes Phase 1a (65 healthy adults) and initiates Phase 1b (20 obese NAFLD patients) of CB4211 trial.
  6. 2021-01
    Reynolds et al. publish landmark exercise/aging study in Nature Communications (PMID 33473109) showing MOTS-c enhances physical performance across all ages.
  7. 2021-08
    CohBar announces positive Phase 1a/1b topline results for CB4211: well-tolerated, ALT -25%, AST -17%, glucose -6% vs placebo.
  8. 2024-01
    The 2024 Prohibited List prohibits AMPK activators as a class; MOTS-c is not named under S0.
  9. 2025-01
    WADA adds MOTS-c as a named AMPK-activator example under S4.4.1 on the 2025 Prohibited List. It is prohibited at all times.
  10. 2025-present
    FDA keeps MOTS-c off its compounding list and lists it among withdrawn nominations with safety concerns. No IND applications for native MOTS-c are publicly known. Research continues primarily in preclinical settings.
  11. 2026-10-28
    HHS draft interim compounding policyHHS posts a draft interim, non-binding enforcement-discretion policy covering 503A compounding of MOTS-c acetate under conditions (Federal Register Doc. 2026-22192, scheduled for Federal Register publication October 30, 2026; open for public comment until mid-November). Not an approval; not added to the 503A bulks list.

Sources & FAQs

Research sources(24)

  1. Lee et al. 2015 — MOTS-c discovery, metabolic homeostasis
  2. Kim et al. 2018 — MOTS-c nuclear translocation and gene regulation
  3. Reynolds et al. 2021 — MOTS-c exercise-induced, physical performance, aging
  4. Kumagai et al. 2021 — MOTS-c reduces myostatin and muscle atrophy
  5. Yin et al. 2022 — MOTS-c in gestational diabetes mellitus
  6. Lu et al. 2019 — MOTS-c prevents ovariectomy-induced metabolic dysfunction
  7. Lu et al. 2019 — MOTS-c increases adipose thermogenesis for cold adaptation
  8. Lee et al. 2016 — MOTS-c review: muscle and fat metabolism
  9. Benayoun & Lee 2019 — MOTS-c as mitochondrial-encoded nuclear regulator
  10. Zheng et al. 2023 — MOTS-c review: therapeutic exploitation
  11. Wan et al. 2023 — MOTS-c effects and mechanisms review
  12. Mohtashami et al. 2022 — MOTS-c in human aging and age-related diseases
  13. Fuku et al. 2015 — MOTS-c polymorphism and exceptional longevity
  14. von Walden et al. 2021 — Acute endurance exercise stimulates circulating MDPs
  15. Dieli-Conwright et al. 2021 — Exercise effects on MOTS-c in breast cancer survivors
  16. Yi et al. 2023 — MOTS-c in bone metabolism regulation
  17. Zhong et al. 2022 — MOTS-c prevents heart failure development
  18. Zhang et al. 2024 — MOTS-c alleviates radiation pneumonitis via Nrf2
  19. Kong et al. 2023 — MOTS-c, diabetes, and aging-related diseases
  20. Yoon et al. 2022 — Exercise, mitohormesis, and MOTS-c
  21. CohBar Phase 1a/1b CB4211 Trial
  22. USADA — What is the MOTS-c peptide?
  23. WADA 2025 Prohibited List
  24. Ikonomidis et al. 2020 — MOTS-c as predictor in diabetic cardiovascular outcomes

Frequently asked questions(5)

Is MOTS-c the same as humanin?

No. Both are mitochondrial-derived peptides (MDPs), but they are distinct molecules encoded in different regions of the mitochondrial genome. MOTS-c is a 16-amino-acid peptide encoded in the 12S rRNA gene, while humanin is a 24-amino-acid peptide encoded in the 16S rRNA gene. They have different mechanisms of action and biological effects, though both have metabolic and cytoprotective properties.

Does MOTS-c actually mimic exercise?

Partially. MOTS-c is upregulated by exercise in both skeletal muscle and circulation, and exogenous administration in mice reproduces some exercise benefits (improved glucose metabolism, enhanced physical performance, AMPK activation, adipose browning). However, exercise has far broader systemic effects than MOTS-c alone. The 'exercise mimetic' label reflects overlapping metabolic pathways, not a complete replacement for physical activity.

Why do MOTS-c levels decline with age?

The exact mechanism is not fully understood, but it likely relates to age-dependent declines in mitochondrial function, reduced mitochondrial DNA copy number, and decreased mitochondrial gene expression. Since MOTS-c is encoded by the mitochondrial genome, deteriorating mitochondrial health directly impacts its production. This age-related decline may contribute to metabolic dysfunction and physical decline associated with aging.

Has MOTS-c been tested in humans?

Native MOTS-c has not been directly administered to humans in any published clinical trial. Human studies have measured endogenous MOTS-c levels as a biomarker in exercise, aging, and disease contexts. The closest human therapeutic trial is CB4211, a stabilized MOTS-c analog, which completed a Phase 1a/1b trial (NCT03998514) enrolling 88 subjects, with 20 of the 23 Phase 1b participants completing assessments, showing good safety but modest efficacy.

Is MOTS-c legal to use?

MOTS-c exists in a regulatory grey area. It is not FDA-approved for human use and is not on FDA's compounding list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies that compound single-ingredient MOTS-c acetate injections for an individual prescription under conditions; that is not an approval. WADA prohibits it for athletes. Self-administration carries risks related to product purity, unknown dosing safety, and lack of medical supervision.